domingo, 30 de octubre de 2016

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. - PubMed - NCBI

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. - PubMed - NCBI



 2016 Oct 13. doi: 10.18632/oncotarget.12633. [Epub ahead of print]

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.

Abstract

OBJECTIVES:

The current gold-standard for the first-line treatment in IIIb/IV stages of epithelial ovarian cancer (EOC) is the combination of carboplatin and paclitaxel plus bevacizumab in some countries. In the era of personalized medicine, there is still uncertainty on the impact of several molecularly targeted agents, which have been investigated for the management of this disease. To shed light on the actual role of targeted therapy in EOC, a systematic review and meta-analysis was performed.

METHODS:

Clinical trials were selected by searching "Pubmed" database and abstracts from major cancer meetings within the time-frame of January 2004-June 2015. The endpoints were survival outcome and response rate (RR). Hazard ratios (HRs) of survival outcomes, with confidence intervals and odds-ratios (ORs) of RR, were extracted from retrieved studies and used for current analysis. Meta-analysis was carried out by random effect model.

RESULTS:

30 randomized trials for a total of 10,530 patients were selected and included in the final analysis. A benefit in terms of OS (pooled HR 0.915; 95%CI 0.840-0.997; p=0.043), particularly for anti-angiogenetic agents (HR 0.872; 95%CI 0.761-1.000; p=0.049), has been demonstrated for targeted therapy. Moreover, a significant advantage in platinum-resistant subgroup in term of PFS (HR 0.755; 95%CI 0.624-0.912; p=0.004) was found.

CONCLUSIONS:

This systematic review and meta-analysis provide the first evidence that targeted therapy is potentially able to translate into improved survival of EOC patients, with a major role played by anti-angiogenetic drugs. The role of target therapy is underlined in the platinum-resistant setting that represents the "pain in the neck" in EOC management.

KEYWORDS:

meta-analysis; ovarian cancer; systematic review; systemic chemotherapy; targeted therapy

PMID:
 
27764790
 
DOI:
 
10.18632/oncotarget.12633

[PubMed - as supplied by publisher] 
Free full text

No hay comentarios:

Publicar un comentario